Turkovac

Source: Wikipedia, the free encyclopedia.
(Redirected from TurkoVac)

Turkovac
Vaccine description
TargetSARS-CoV-2
Vaccine typeInactivated
Clinical data
Other namesERUCOV-VAC
Routes of
administration
Intramuscular
Legal status
Legal status

Turkovac[1] (pronunciation: ['tɜ:rkəvæk]) is a COVID-19 vaccine developed by Turkish Ministry of Health and Erciyes University.

Clinical trials

In November 2020, TURKOVAC started on phase I trials with 44 participants in Turkey.[2]

In February 2021, TURKOVAC started on phase II trials with 250 participants in Turkey.[3]

In June 2021, TURKOVAC started on phase III trials with 40,800 participants in Turkey.[4] As of 2023 phase III trials continue.[5]

Authorization

On 25 November 2021, the Turkish Minister of Health reported that Turkovac's application for emergency use authorization had been filed.[6] On 22 December, Turkish President Recep Tayyip Erdogan announced the emergency use approval of Turkovac.[7]

References

  1. ^ Cakmak BN (22 June 2021). "Turkey names home-grown COVID-19 jab Turkovac". Anadolu Agency.
  2. ^ Clinical trial number NCT04691947 for "Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC (ERUCOV-VAC)" at ClinicalTrials.gov
  3. ^ Clinical trial number NCT04824391 for "Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19 " at ClinicalTrials.gov
  4. ^ "Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine". ClinicalTrials.gov. 28 June 2021. NCT04942405. Retrieved 29 June 2021.
  5. ^ "ClinicalTrials.gov". www.clinicaltrials.gov. Retrieved 16 January 2024.
  6. ^ "Turkey issues emergency-use authorization for its domestically produced vaccine". The New York Times. 22 December 2021. Retrieved 28 December 2021.
  7. ^ "Turkey authorises use of own Turkovac Covid-19 vaccine". France 24. 23 December 2021. Retrieved 24 December 2021.